Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

arnolds of reading c/- virbac - trimethoprim | sulfadiazine - antibacterial

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - lamivudine 150mg;   - film coated tablet - 150 mg - active: lamivudine 150mg   excipient: magnesium stearate microcrystalline cellulose opadry white ys-1-7706-g sodium starch glycolate - 3tc in combination with other anti-retroviral agents is indicated for the treatment of hiv infected adults and children.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - lamivudine 10 mg/ml;   - oral solution - 10 mg/ml - active: lamivudine 10 mg/ml   excipient: banana flavour 59.256 ap0551 citric acid methyl hydroxybenzoate propyl hydroxybenzoate propylene glycol purified water sodium citrate dihydrate strawberry flavour 057883 ap0551 sucrose - 3tc in combination with other anti-retroviral agents is indicated for the treatment of hiv infected adults and children.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

lekhim-kharkiv jsc - diclofenac (diclofenac sodium) - solution for i/m and i/v injection - 25mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.25mg;  ;  ;  ;  ; digoxin 0.25mg - tablet - 0.25 mg - active: digoxin 0.25mg         excipient: lactose monohydrate magnesium stearate maize starch pregelatinised maize starch purified water rice starch active: digoxin 0.25mg excipient: lactose monohydrate magnesium stearate maize starch purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.05 mg/ml;   - elixir - 0.05 mg/ml - active: digoxin 0.05 mg/ml   excipient: citric acid monohydrate dibasic sodium phosphate ethanol lime flavour 70.80.0303 methyl hydroxybenzoate propylene glycol purified water quinoline yellow sucrose - lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.0625mg;  ;  ;  ;  ; digoxin 0.0625mg - tablet - 0.0625 mg - active: digoxin 0.0625mg         excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone pregelatinised maize starch purified water rice starch active: digoxin 0.0625mg excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.